Abstract
The importance of the phosphatidylinositol-3-kinase (PI3K) pathway in cell survival and proliferation has made it an attractive target in cancer therapy. The development of small molecule inhibitors for the PI3K pathway continues to provide treatment alternatives across a range of malignancy types. Several agents, including idelalisib, copanlisib and duvelisib, not only inhibit the PI3K pathway, but also have effects on associated mechanisms including the ATK and mTOR pathways. The advent of PI3K-specific small molecular inhibitors has led to increased efficacy with avoidance of an excessive toxicity profile. Key enzymes of the PI3K pathway exhibit differing expression in tissue types and roles in tumor pathogenesis. Copanlisib (BAY 80-6946) is a pan-specific PI3K small molecule inhibitor for four key isoforms with increased activity against PI3Kα and PI3Kδ, both important in B-cell malignancies. Follicular lymphoma is one of the most common indolent B-cell non-Hodgkin lymphomas worldwide. Follicular lymphoma like other indolent B-cell non-Hodgkin lymphomas is beleaguered by high relapse rates and the need for subsequent therapy options. Based on efficacy and a limited toxicity profile, copanlisib received accelerated US Food a...Continue Reading
Citations
Mar 1, 2019·Biomolecules·Michelle S MillerSandra B Gabelli
Oct 12, 2019·BMC Cancer·Joo Hyun KimChaehwa Park
Mar 21, 2020·Clinical Journal of Oncology Nursing·Barbara B Rogers
May 20, 2020·Cellular & Molecular Immunology·Xiaoguang WangJing H Wang
Jun 25, 2020·Expert Review of Clinical Pharmacology·Massimo MagagnoliArmando Santoro
Dec 21, 2018·International Journal of Molecular Sciences·Angelo MaffeiDaniela Carnevale
Mar 5, 2020·Oncogene·Xiaochen LiuYaoqin Gong
Jan 24, 2019·International Journal of Molecular Sciences·Vanessa Edna SanchezYong-Mi Kim
Jul 10, 2019·Cancers·Alia Ghoneum, Neveen Said
May 2, 2020·Current Treatment Options in Oncology·Vladimir Sapon-CousineauSarit Assouline
Sep 22, 2020·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Olivia G FaheyElizabeth N Dow-Hillgartner
Jun 12, 2020·Clinical Microbiology Reviews·Joshua S DavisMichael Boyle
Nov 3, 2020·Leukemia & Lymphoma·Philipp Berning, Georg Lenz
Jun 6, 2020·Molecular Cancer Therapeutics·Samantha PerinoKerry A Whalen
Dec 5, 2020·Cancer Science·Hiroo ImaiChikashi Ishioka
Nov 4, 2020·Cell Death & Disease·Ji YanHongmei Zhao
Nov 21, 2020·Expert Opinion on Drug Metabolism & Toxicology·Marion BerthoMario Campone
Mar 10, 2021·Targeted Oncology·Javier MunozLoretta J Nastoupil
Mar 7, 2021·Cancers·Chiara PediconeWilliam G Kerr
Nov 7, 2020·Frontiers in Oncology·Laura Ondrisova, Marek Mraz
Aug 3, 2021·Cell Reports Medicine·Ana PortelinhaSanjeeva Reddy
Jan 28, 2022·Expert Opinion on Therapeutic Targets·Ahsan Anjoom Sunil, Tom Skaria